U.S. support for legalizing cannabis for medicinal use has hit a new record-high: 91%. Strong bipartisan support. Next: psychedelic drugs.

Numinus’ Phase I clinical trial will evaluate safety/tolerance properties of its Psilocybe mushroom product.

The Montana-based Crow Tribe last week approved an ordinance to oversee its own cannabis cultivation and sales, and allow the tribe to benefit from the proceeds, the Associated Press reports.

A psychedelic trip can be among the most sacred experiences of a person’s life.

Champignon Brands has had its Cease Trade Order lifted and can resume trading on the CSE effective April 23, 2021 (symbol: SHRM).

Low share prices. VERY low trading volumes. The slump in psychedelic stocks in 2021 looks a lot like the slump in 2020.

LUCID’s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback

With atai Life Sciences filing for a $100 million IPO financing, the countdown to IPO day has begun.

Mental illness is the 21st century’s leading cause of disability, affecting an estimated billion people across the world.